Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Denise Gavin"'
Autor:
Ying Huang, Mike Havert, Denise Gavin, Mercedes Serabian, Lee Lee Ong, Maritza C McIntyre, Nicolas Ferry, Akihiro Kume, Dino Petrin, Ying-Hsien Fu, Andreas Marti, Fabricio Oliveira, Sumol Pavittranon, Won Shin
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 3, Iss C (2016)
Externí odkaz:
https://doaj.org/article/ae39334902ff4e1a937b3387f432aba3
Autor:
Richard Pazdur, Marc R. Theoret, Wilson Bryan, Bindu George, Ke Liu, Shiowjen Lee, Denise Gavin, Donna Przepiorka, Iftekhar Mahmood, Xue Lin, Ying Huang, Xiaobin Lu, Maura C. O'Leary
Tisagenlecleucel (Kymriah; Novartis Pharmaceuticals) is a CD19-directed genetically modified autologous T-cell immunotherapy. On August 30, 2017, the FDA approved tisagenlecleucel for treatment of patients up to 25 years of age with B-cell precursor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2778be6639e61d1ae5fc84f9d9a78cf3
https://doi.org/10.1158/1078-0432.c.6526745
https://doi.org/10.1158/1078-0432.c.6526745
Autor:
Richard Pazdur, Marc R. Theoret, Wilson Bryan, Bindu George, Ke Liu, Shiowjen Lee, Denise Gavin, Donna Przepiorka, Iftekhar Mahmood, Xue Lin, Ying Huang, Xiaobin Lu, Maura C. O'Leary
Supplementary Table S1, S2, Supplementary Figure S1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a2cea1889b74960132489534531ab7c
https://doi.org/10.1158/1078-0432.22467788
https://doi.org/10.1158/1078-0432.22467788
Autor:
Shiowjen Lee, Wilson Bryan, Marc R. Theoret, Maura C. O'Leary, Iftekhar Mahmood, Bindu George, Xue Lin, Richard Pazdur, Ke Liu, Xiaobin Lu, Ying Huang, Denise Gavin, Donna Przepiorka
Publikováno v:
Clinical Cancer Research. 25:1142-1146
Tisagenlecleucel (Kymriah; Novartis Pharmaceuticals) is a CD19-directed genetically modified autologous T-cell immunotherapy. On August 30, 2017, the FDA approved tisagenlecleucel for treatment of patients up to 25 years of age with B-cell precursor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e25b979680b87e37dc4421ef6b09259c
https://doi.org/10.1158/1078-0432.ccr-18-2035
https://doi.org/10.1158/1078-0432.ccr-18-2035
Autor:
Andreas Marti, Nicolas Ferry, Ying-Hsien Fu, Fabricio Oliveira, Sumol Pavittranon, Denise Gavin, Lee Lee Ong, Ying Huang, Mike Havert, Dino Petrin, Maritza C McIntyre, Akihiro Kume, Won Shin, Mercedes Serabian
Publikováno v:
Molecular Therapy. Methods & Clinical Development
Molecular Therapy: Methods & Clinical Development, Vol 3, Iss C (2016)
Molecular Therapy: Methods & Clinical Development, Vol 3, Iss C (2016)
On 15 May 2015 during the 18th Annual American Society of Gene and Cell Therapy (ASGCT) Meeting1 regulators from the International Pharmaceutical Regulators Forum Gene Therapy Working Group presented current expectations of various international regu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::efe9aec6d1199c03055d7c206ad163e1
https://doi.org/10.1038/mtm.2016.22
https://doi.org/10.1038/mtm.2016.22